Nuoshan Technology Secures Tens of Millions RMB in Seed Funding to Advance Preclinical Research of Full-Function Microfluidic Organoid-on-a-Chip Platform

VCBeat recently learned that Beijing Nuoshan Technology Co., Ltd. (“Nuoshan Technology”) has completed an angel financing round worth tens of millions of RMB. This round was exclusively invested by SEE FUND, and the funds will be used for preclinical research on the company’s fully functional microfluidic organ-on-a-chip technology.

Nuoshan Technology was established in January 2024, with its core team and technology originating from Beijing Institute of Technology and Peking Union Medical College Hospital. The Nuoshan Technology team has long been deeply engaged in research on microfluidic chips and their applications in clinical medicine, possessing leading domestic capabilities in the development of complex, fully functional microfluidic chips.Supported by multiple national-level research initiatives, including the National Key R&D Program of China, the team has focused on developing a fully functional microfluidic chip for lung cancer drug sensitivity testing. The chip prototype has been completed, and the team has conducted China’s first prospective clinical cohort study on cancer drug sensitivity testing based on microfluidic chips at Peking Union Medical College Hospital.

Professor Wei Zewen, Founder of Nuoshan Technologystated: “We extend our heartfelt gratitude to the investment institutions for their strong support of our startup team, completing the investment within just one month of the company’s establishment. We are an interdisciplinary team integrating medicine and engineering, having dedicated ourselves to organoid research over the past several years. Our efforts have yielded first-class scientific achievements and secured support from national-level research projects totaling over RMB 10 million. Organoid technology has undergone several years of development and accumulation in China. We believe that the key bottlenecks to commercializing organoid technology lie in achieving true standardization and automation, as well as demonstrating clinical benefits supported by high-quality clinical trial evidence. Only by addressing these challenges can we penetrate hospital-end and business-to-business (B-end) markets and achieve scaled sales. We are confident that, with our fully functional microfluidic chip as the core, we will revolutionize existing multi-well plate or open microarray-based organoid culture and analysis methods, thereby gaining recognition for organoid analysis technologies and equipment among both institutions and patients.”

Ning Xingzhi, Partner at SEE FUND“It stated: ‘Whether it is precision medicine tailored to individual patient differences on the clinical side, or the acceleration of new drug development through high-efficiency simulated disease models on the R&D side, organoids hold immense potential to address industry pain points and possess significant long-term value. Organoids are currently in an accelerated validation phase, with a future potential market space reaching tens of billions. We are highly optimistic about Nuoshan Technology’s team, given their interdisciplinary background in medicine and engineering, robust hard-tech capabilities, extensive clinical resources, and clinical-need-driven R&D approach. We believe that Nuoshan Technology will complete the development and regulatory approval of its organoid-based drug sensitivity testing equipment according to schedule, thereby leading the standardization and automation trends in the organoid industry and accelerating the progress of precision medicine in China and globally.’”

SEE Fund is an early-stage investment firm originating from Tsinghua University, with a focus on electronic information, new materials, and life and health sectors. SEE Fund brings together top domestic investment institutions and industrial resources, aiming to promote innovation and entrepreneurship through market-oriented mechanisms, empower entrepreneurs, and leverage technology for the benefit of humanity. In the life and health sector, SEE Fund prioritizes areas such as medical-engineering integration, AI interdisciplinary applications, and synthetic biology. Its investment portfolio includes Tupai Medical, Microstructure Factory, and Fumailie.